Preclinical evaluation of genexol-pm, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 463-468

  Werner, Michael E ^a   Cummings, Natalie D ^a   Sethi, Manish ^a   Wang, Edina C ^a   Sukumar, Rohit ^a   Moore, Dominic T ^b   Wang, Andrew Z ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; CELL CULTURE; CELLS; CHEMORADIOTHERAPY; CYTOLOGY; DISEASE CONTROL; DISEASES; DRUG PRODUCTS; MAMMALS; NANOPARTICLES; ONCOLOGY; RADIOTHERAPY;

CHEMORADIATION THERAPIES; CLINICAL TRANSLATION; CONTROLLED DRUG RELEASE; INHIBITORY CONCENTRATION; METHODS AND MATERIALS; NANOPARTICLE FORMULATION; NON SMALL CELL LUNG CANCER; PHYSICAL CHARACTERISTICS;

BIOLOGICAL ORGANS;

PACLITAXEL; RADIOSENSITIZING AGENT; ANTINEOPLASTIC AGENT; NANOPARTICLE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HALF MAXIMAL INHIBITORY CONCENTRATION; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RADIOSENSITIZATION; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; LUNG; LUNG TUMOR; METHODOLOGY; NUDE MOUSE; PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMORADIOTHERAPY; LUNG; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; PACLITAXEL; POLYMERS; RADIATION-SENSITIZING AGENTS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84880625081     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.009     Document Type: Article

References (20)

1. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigmdgeneral principles. Nat Clin Pract Oncol 2007;4:86-100.
2. Eifel PJ. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol 2006;16:177-185.
3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
4. Rasch CR, Hauptmann M, Schornagel J, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial. Cancer 2010;116:2159-2165.
5. Wang AZ, Langer RS, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. Annu Rev Med 2012;63:185-198.
6. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15: 440-449.
7. Werner ME, Copp JA, Karve S, et al. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano 2011;5:8990-8998.
8. Jung J, Park SJ, Chung HK, et al. Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in nonesmall cell lung cancer. Int J Radiat Oncol Biol Phys 2012;84:e77-e83.
9. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108:241-250.
10. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-2014.
11. Lim WT, Tan EH, Toh CK, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 2010;21:382-388.
12. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23: 5910-5917.
13. Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ 1990;300:230-235.
14. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 2008;83: 761-769.
15. Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010;15:1227-1237.
16. Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 2012;13:395-406.
17. Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 2012;41:2971-3010.
18. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507.
19. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994; 86:441-446.
20. Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001;93:1806-1811.